The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet
Creatine monohydrate has been developed as a neuroprotective agent and can penetrate in vitro model of the blood-brain barrier. However, its delivery is hampered by its limited capacity of creatine transporter. The floating system is known to increase the residence time of drugs in the stomach; thus...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
LPPT Universitas Gadjah Mada
2023-12-01
|
| Series: | Journal of Food and Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | https://jurnal.ugm.ac.id/v3/JFPS/article/view/8284/3309 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589844977549312 |
|---|---|
| author | Arifatu Nur Hidayah Anas Ardiana Wati Nunung Yuniarti Marlyn Dian Laksitorini |
| author_facet | Arifatu Nur Hidayah Anas Ardiana Wati Nunung Yuniarti Marlyn Dian Laksitorini |
| author_sort | Arifatu Nur Hidayah |
| collection | DOAJ |
| description | Creatine monohydrate has been developed as a neuroprotective agent and can penetrate in vitro model of the blood-brain barrier. However, its delivery is hampered by its limited capacity of creatine transporter. The floating system is known to increase the residence time of drugs in the stomach; thus, the active substances can be absorbed more optimally. Therefore, this study is aimed to develop creatine monohydrate floating tablets by optimizing the proportion of HPMC K100M and NaHCO2 and evaluating the quality of floating tablets. The formula was designed Simplex Lattice Design method. Tablets were prepared by the wet granulation method and evaluated for granule and tablet parameters. The results showed that HPMC K100M significantly increased flow time, absorption rate, hardness, floating time, swelling index; decreased index tap, fragility, and floating lag time. Meanwhile, an increase in NaHCO2 significantly affects an increase in floating lag time. The optimum formula obtained was 18.87% HPMC K100M and 21.12% NaHCO2. Verification of the optimum formula showed that tablet parameters were not significantly different from the predicted formula. The studies suggest that this prototype can be developed to increase creatine residence time in the stomach. |
| format | Article |
| id | doaj-art-6899dd1fe576471fb349443722dd4d66 |
| institution | Kabale University |
| issn | 2089-7200 2339-0948 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | LPPT Universitas Gadjah Mada |
| record_format | Article |
| series | Journal of Food and Pharmaceutical Sciences |
| spelling | doaj-art-6899dd1fe576471fb349443722dd4d662025-01-24T07:57:25ZengLPPT Universitas Gadjah MadaJournal of Food and Pharmaceutical Sciences2089-72002339-09482023-12-0111388989910.22146/jfps.8284The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating TabletArifatu Nur Hidayah0Anas Ardiana Wati1Nunung Yuniarti2Marlyn Dian Laksitorini3Undergraduate Program, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, IndonesiaUndergraduate Program, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.Departement of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, IndonesiaDepartement of Pharmaceutics, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.Creatine monohydrate has been developed as a neuroprotective agent and can penetrate in vitro model of the blood-brain barrier. However, its delivery is hampered by its limited capacity of creatine transporter. The floating system is known to increase the residence time of drugs in the stomach; thus, the active substances can be absorbed more optimally. Therefore, this study is aimed to develop creatine monohydrate floating tablets by optimizing the proportion of HPMC K100M and NaHCO2 and evaluating the quality of floating tablets. The formula was designed Simplex Lattice Design method. Tablets were prepared by the wet granulation method and evaluated for granule and tablet parameters. The results showed that HPMC K100M significantly increased flow time, absorption rate, hardness, floating time, swelling index; decreased index tap, fragility, and floating lag time. Meanwhile, an increase in NaHCO2 significantly affects an increase in floating lag time. The optimum formula obtained was 18.87% HPMC K100M and 21.12% NaHCO2. Verification of the optimum formula showed that tablet parameters were not significantly different from the predicted formula. The studies suggest that this prototype can be developed to increase creatine residence time in the stomach.https://jurnal.ugm.ac.id/v3/JFPS/article/view/8284/3309floating tabletcreatine monohydratehpmc k100mnahco2 |
| spellingShingle | Arifatu Nur Hidayah Anas Ardiana Wati Nunung Yuniarti Marlyn Dian Laksitorini The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet Journal of Food and Pharmaceutical Sciences floating tablet creatine monohydrate hpmc k100m nahco2 |
| title | The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet |
| title_full | The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet |
| title_fullStr | The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet |
| title_full_unstemmed | The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet |
| title_short | The Development of Alternative Dosage Form for Creatine Monohydrate: A Floating Tablet |
| title_sort | development of alternative dosage form for creatine monohydrate a floating tablet |
| topic | floating tablet creatine monohydrate hpmc k100m nahco2 |
| url | https://jurnal.ugm.ac.id/v3/JFPS/article/view/8284/3309 |
| work_keys_str_mv | AT arifatunurhidayah thedevelopmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT anasardianawati thedevelopmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT nunungyuniarti thedevelopmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT marlyndianlaksitorini thedevelopmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT arifatunurhidayah developmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT anasardianawati developmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT nunungyuniarti developmentofalternativedosageformforcreatinemonohydrateafloatingtablet AT marlyndianlaksitorini developmentofalternativedosageformforcreatinemonohydrateafloatingtablet |